A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Trial ID or NCT#
Status
Purpose
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Official Title
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Eligibility Criteria
- * Known current central nervous system disease involvement or untreated brain metastases* Allogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement* History of hemolytic anemia or bleeding diathesis
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Elle (Hyunjin) Kim
650-387-4436
View on ClinicalTrials.gov